Your browser is no longer supported. Please, upgrade your browser.
Settings
SYRS Syros Pharmaceuticals, Inc. daily Stock Chart
SYRS [NASD]
Syros Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.70 Insider Own0.80% Shs Outstand45.70M Perf Week28.56%
Market Cap549.73M Forward P/E- EPS next Y-1.63 Insider Trans-35.04% Shs Float40.83M Perf Month2.26%
Income-73.90M PEG- EPS next Q-0.39 Inst Own89.10% Short Float7.20% Perf Quarter25.77%
Sales6.60M P/S83.29 EPS this Y1.70% Inst Trans0.38% Short Ratio8.92 Perf Half Y71.59%
Book/sh1.37 P/B8.91 EPS next Y-3.80% ROA-49.00% Target Price12.86 Perf Year35.11%
Cash/sh- P/C- EPS next 5Y- ROE-94.60% 52W Range4.26 - 12.75 Perf YTD76.56%
Dividend- P/FCF- EPS past 5Y-22.20% ROI-97.20% 52W High-4.31% Beta1.55
Dividend %- Quick Ratio4.80 Sales past 5Y- Gross Margin- 52W Low186.38% ATR0.84
Employees83 Current Ratio4.80 Sales Q/Q540.00% Oper. Margin- RSI (14)60.39 Volatility8.24% 7.21%
OptionableYes Debt/Eq0.33 EPS Q/Q19.40% Profit Margin- Rel Volume0.76 Prev Close12.03
ShortableYes LT Debt/Eq0.32 EarningsAug 06 BMO Payout- Avg Volume329.81K Price12.20
Recom2.10 SMA209.05% SMA5015.51% SMA20058.28% Volume249,895 Change1.41%
Jan-17-20Downgrade Wedbush Outperform → Neutral
Mar-08-19Resumed JMP Securities Mkt Outperform $18
Feb-14-19Resumed Oppenheimer Outperform $13
Nov-05-18Upgrade ROTH Capital Neutral → Buy
Mar-13-18Reiterated Wedbush Outperform $11 → $13
Oct-31-17Resumed Piper Jaffray Overweight $30
Oct-23-17Initiated ROTH Capital Neutral $15
Aug-10-17Downgrade JMP Securities Mkt Outperform → Mkt Perform
Aug-06-20 09:55AM  
07:31AM  
Aug-05-20 09:09AM  
Jul-30-20 12:34PM  
08:30AM  
Jul-07-20 08:00AM  
Jul-05-20 02:45PM  
Jun-17-20 08:00AM  
Jun-15-20 06:31AM  
Jun-11-20 08:31AM  
May-29-20 08:01AM  
May-28-20 08:00AM  
May-19-20 07:22AM  
May-13-20 05:01PM  
May-12-20 10:32AM  
May-08-20 02:31PM  
May-07-20 10:05AM  
08:08AM  
07:30AM  
May-06-20 10:01AM  
Apr-30-20 08:30AM  
Apr-29-20 12:34PM  
Apr-07-20 09:30AM  
Mar-26-20 10:16AM  
Mar-22-20 10:27AM  
Mar-05-20 08:45AM  
07:30AM  
Feb-27-20 12:30PM  
08:00AM  
Feb-24-20 08:00AM  
Feb-13-20 08:00AM  
Feb-06-20 02:03PM  
Jan-29-20 08:31AM  
Jan-28-20 08:31AM  
Jan-15-20 08:29AM  
Jan-12-20 09:00AM  
Dec-20-19 11:40AM  
08:01AM  
Dec-19-19 05:20PM  
08:00AM  
Dec-18-19 07:51AM  
07:15AM  
07:00AM  
Dec-16-19 07:35AM  
Dec-08-19 08:00AM  
Dec-03-19 11:44PM  
Dec-02-19 01:50PM  
Nov-26-19 08:31AM  
08:31AM  
Nov-19-19 07:01AM  
Nov-12-19 09:25AM  
08:00AM  
Nov-06-19 06:09PM  
09:01AM  
Nov-05-19 08:30AM  
Oct-31-19 10:34AM  
Oct-29-19 04:01PM  
Oct-25-19 08:47AM  
Oct-24-19 08:31AM  
Oct-17-19 07:00AM  
Sep-20-19 02:55PM  
Sep-13-19 10:24AM  
Aug-27-19 01:59AM  
Aug-06-19 04:01PM  
Aug-02-19 10:24PM  
Aug-01-19 09:05AM  
Jul-25-19 08:30AM  
Jun-27-19 07:25AM  
07:23AM  
Jun-12-19 08:31AM  
08:01AM  
May-07-19 08:31AM  
May-06-19 09:17AM  
May-02-19 07:59AM  
May-01-19 11:24PM  
08:55AM  
07:30AM  
Apr-24-19 08:01AM  
Apr-17-19 08:01AM  
Apr-09-19 04:01PM  
Apr-05-19 01:41PM  
07:48AM  
07:15AM  
Apr-04-19 04:18PM  
Apr-02-19 04:01PM  
Mar-13-19 02:03AM  
Mar-12-19 02:17PM  
Mar-07-19 12:50PM  
07:30AM  
Mar-06-19 08:31AM  
Feb-28-19 08:30AM  
Feb-27-19 04:31PM  
Feb-05-19 08:20AM  
Jan-06-19 05:00PM  
Jan-03-19 08:01AM  
Dec-21-18 08:01AM  
Dec-07-18 08:01AM  
Dec-02-18 12:01PM  
Nov-30-18 08:30AM  
Nov-20-18 08:01AM  
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Young Richard ADirectorJul 15Sale11.855,99070,982353,171Jul 17 04:11 PM
Olson Eric RChief Scientific OfficerJul 07Sale11.721,75320,5380Jul 07 07:33 PM
AKKARAJU SRINIVASDirectorJul 01Sale11.014,62750,9661,433,943Jul 06 04:00 PM
AKKARAJU SRINIVASDirectorJun 25Sale11.1554,972612,8501,438,570Jun 25 08:38 PM
AKKARAJU SRINIVASDirectorJun 24Sale11.0748,775539,7881,493,542Jun 25 08:38 PM
AKKARAJU SRINIVASDirectorJun 23Sale11.1150,953565,9301,542,317Jun 25 08:38 PM
Young Richard ADirectorJun 15Sale8.755,99052,413359,161Jun 16 04:53 PM
Young Richard ADirectorMay 15Sale9.225,99055,242365,151May 15 05:13 PM
Alles Mark JDirectorMay 13Buy8.8610,00088,59010,000May 13 05:05 PM
Young Richard ADirectorApr 15Sale8.7523,960209,650371,141Apr 17 04:02 PM
Olson Eric RChief Scientific OfficerFeb 18Sale7.381,44610,6740Feb 20 04:15 PM
Simonian Nancy APresident & CEODec 23Option Exercise3.0452,401159,299533,689Dec 23 04:54 PM
Springhorn Jeremy P.Chief Business OfficerNov 12Buy4.9710,12150,26835,000Nov 12 04:34 PM
Springhorn Jeremy P.Chief Business OfficerNov 11Buy4.999,87949,32824,879Nov 12 04:34 PM